The American Association for Cancer Research-Novocure Career Development Award for Cancer Research represents a joint effort to promote and support early-career investigators who are conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage early-career investigators to enter the TTFields research field.
The American Association for Cancer Research will honor the following cancer researchers and physician-scientists during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago.
Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation delayed KRAS-mutated PDAC development in mice, according to results of a study published in Cancer Research, a journal of the American Association for Cancer Research.
The members of the American Association for Cancer Research have elected Keith T. Flaherty, fellow of the AACR Academy, as the AACR president-elect for 2025-2026.
I was really excited to get to talk about the role that mentorship plays in women’s leadership development. It’s a topic that I’ve thought a lot about, and also that I’ve benefitted from, and that I think is not always applied with enough intention. There is an art to mentorship, and I want to share some of how that has helped me navigate career transitions and pivot to leadership roles.
The American Association for Cancer Research named its newly elected 2025 class of fellows of the AACR Academy.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
Daniel K. Nomura was named editor-in-chief of Molecular Cancer Therapeutics, one of the 10 journals published by the American Association for Cancer Research.
Preclinical data on a development candidate, NTX-452, a novel Werner syndrome helicase inhibitor, was presented at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, by Nimbus Therapeutics.
Daniel J. Drucker will be awarded the American Association for Cancer Research 21st AACR-Irving Weinstein Foundation Distinguished Lectureship during the 2025 AACR annual meeting, to be held April 25-30 in Chicago, Illinois.
